Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug for non-small cell lung cancer shows efficacy

22.10.2003


Shrinks tumors in some patients and reduces symptoms in others



A new anti-cancer agent designed to block the signals responsible for telling cancer cells to grow has shown promising results for patients with advanced non-small cell lung cancer. The results of a double blind, randomized trial of the compound, gefinitib (Iressa), led by Dr. Mark Kris, chief of thoracic oncology at Memorial Sloan-Kettering Cancer Center, are published in the October 22 Journal of the American Medical Association. A subset of the data from this clinical trial formed the basis for approval of the drug by the Food and Drug Administration on May 5, 2003.

"This compound is the first new way to treat lung cancer in decades, and this is good news," said Dr. Kris, lead investigator of the multi-center trial. "It is what all people trying to fight cancer want; a pill that specifically attacks the cancer yet does little to adversely effect the person."


Gefinitib is a "designer" drug that targets and blocks an enzyme called tyrosine kinase, part of the epidermal growth factor receptor. Found on the cell surface, the epidermal growth factor receptor is over-expressed in many non-small cell lung cancers. When the epidermal growth factor response is activated, it signals tumor cells to proliferate and grow. When the signal is disrupted, the tumors regress and apoptosis or cell death occurs.

A double-blind, randomized phase II clinical trial of gefinitib was conducted at thirty academic and community oncology centers in the United States. Participating were 221 patients who had either stage IIIB or IV non-small cell lung cancer for which they had received at least two prior chemotherapy regimens. The drug, taken in pill form, was taken daily in doses of either 500 mg (administered as two 250 mg gefinitib tablets) or 250 mg (administered as one 250 mg gefinitib tablet and a matching placebo). Of the 221 patients enrolled, 216 received the randomized doses.

An improvement of their symptoms that included shortness of breath, cough, loss of appetite, tightness in the chest, and weight loss was seen in 43 percent of the patients receiving the 250 mg dose and 35 percent of patients receiving the 500 mg dose reported. This improvement was seen within three weeks for 73 percent of the patients who responded. Partial responses were observed radiographically in 12 per cent of the patients receiving the 250 mg dose and 9 percent of patients on the 500 mg dose. Symptoms improved in 96 percent of the patients with partial radiographic responses. The overall survival at one year was 25 percent. There was no significant difference between the 250 mg and 500 mg doses in rates of symptom improvement, radiographic tumor regression and projected 1-year survival.

For all patients, the drug was well tolerated with few toxic side effects. These consisted mainly of mild diarrhea and an acne-like skin rash and the effects were seen more frequently in patients receiving the 500 mg doses. All side effects were reversible when drug use was stopped. The Food and Drug Administration approved the 250 mg. dose of gefinitib for treatment of advanced non-small cell lung cancer.

"For patients with metastatic lung cancer who have no other options, lessening their symptoms without adding burdensome side effects is a very real benefit," said Dr. Kris. "It gives hope that with more research and improved targets, we will do even better."

This study was conducted by Memorial Sloan-Kettering; Cedars-Sinai Comprehensive Cancer Center; M.D. Anderson Cancer Center; Massachusetts General Cancer Center; UCLA Medical Center; University of Pittsburgh Cancer Institute; University of Wisconsin Hospital - Madison; University of Colorado Health Sciences Center; Hematology-Oncology Consultants, Inc. of Columbus, Ohio; Vanderbilt University; Loyola University Medical Center; and Northwestern University. The study was sponsored by AstraZeneca Pharmaceuticals, developer of the study drug.


Memorial Sloan-Kettering Cancer Center is the world’s oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org.

Joanne Nicholas | EurekAlert!
Further information:
http://www.mskcc.org/

More articles from Health and Medicine:

nachricht Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>